Is EDSA or MOLN more profitable?

Molecular Partners' return on equity of -68.36% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Molecular Partners N/A -68.36% -54.82%

Which has better valuation & earnings, EDSA or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.69 N/A NervGen Pharma N/A N/A -$31.58M -$0.46 N/A

Is EDSA or NGEN more profitable?

Edesa Biotech's return on equity of -560.22% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% NervGen Pharma N/A -1,259.82% -199.79%

Does the media prefer EDSA or NGEN?

In the previous week, Edesa Biotech and Edesa Biotech both had 2 articles in the media. Edesa Biotech's average media sentiment score of 1.27 beat NervGen Pharma's score of 0.94 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EDSA or SPRB more profitable?

Spruce Biosciences' return on equity of -123.53% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Spruce Biosciences N/A -123.53% -90.35%

Does the media favor EDSA or SPRB?

In the previous week, Edesa Biotech and Edesa Biotech both had 2 articles in the media. Edesa Biotech's average media sentiment score of 1.27 beat Spruce Biosciences' score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EDSA or HUMA more profitable?

Edesa Biotech has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Edesa Biotech's return on equity of -560.22% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Humacyte -4,556.29% -983.32% -88.84%

Does the media prefer EDSA or HUMA?

In the previous week, Humacyte had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.27 beat Humacyte's score of 0.92 indicating that Edesa Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Edesa Biotech (EDSA) Competitors

$4.36 +0.13 (+3.07%)

As of 11:13 AM Eastern

Compare

EDSA vs. MOLN, NGEN, SPRB, HUMA, and CRBU

Should you buy Edesa Biotech stock or one of its competitors? Edesa Biotech's main competitors and comparable companies include Molecular Partners (MOLN), NervGen Pharma (NGEN), Spruce Biosciences (SPRB), Humacyte (HUMA), and Caribou Biosciences (CRBU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Edesa Biotech compare to Molecular Partners?

Edesa Biotech (NASDAQ:EDSA) and Molecular Partners (NASDAQ:MOLN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 14.68%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 101.81%. Given Molecular Partners' higher possible upside, analysts clearly believe Molecular Partners is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Edesa Biotech has higher earnings, but lower revenue than Molecular Partners. Edesa Biotech is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Molecular Partners	$5.65M	29.66	-$74.41M	-$1.71	N/A

In the previous week, Edesa Biotech had 1 more articles in the media than Molecular Partners. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.87 beat Edesa Biotech's score of 1.27 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Edesa Biotech	Positive
Molecular Partners	Very Positive

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 5.9% of Molecular Partners shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Edesa Biotech has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Molecular Partners' return on equity of -68.36% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Molecular Partners	N/A	-68.36%	-54.82%

Summary

Molecular Partners beats Edesa Biotech on 9 of the 15 factors compared between the two stocks.

How does Edesa Biotech compare to NervGen Pharma?

Edesa Biotech (NASDAQ:EDSA) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Edesa Biotech's return on equity of -560.22% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
NervGen Pharma	N/A	-1,259.82%	-199.79%

5.5% of Edesa Biotech shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NervGen Pharma is trading at a lower price-to-earnings ratio than Edesa Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

In the previous week, Edesa Biotech and Edesa Biotech both had 2 articles in the media. Edesa Biotech's average media sentiment score of 1.27 beat NervGen Pharma's score of 0.94 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech currently has a consensus target price of $5.00, suggesting a potential upside of 14.68%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 536.65%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

Edesa Biotech beats NervGen Pharma on 7 of the 12 factors compared between the two stocks.

How does Edesa Biotech compare to Spruce Biosciences?

Edesa Biotech (NASDAQ:EDSA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Edesa Biotech has higher earnings, but lower revenue than Spruce Biosciences. Edesa Biotech is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Spruce Biosciences	$4.91M	31.68	-$38.97M	-$39.78	N/A

In the previous week, Edesa Biotech and Edesa Biotech both had 2 articles in the media. Edesa Biotech's average media sentiment score of 1.27 beat Spruce Biosciences' score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spruce Biosciences' return on equity of -123.53% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Spruce Biosciences	N/A	-123.53%	-90.35%

Edesa Biotech has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market.

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 14.68%. Spruce Biosciences has a consensus price target of $159.50, indicating a potential upside of 194.28%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Spruce Biosciences beats Edesa Biotech on 9 of the 14 factors compared between the two stocks.

How does Edesa Biotech compare to Humacyte?

Edesa Biotech (NASDAQ:EDSA) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Edesa Biotech has a net margin of 0.00% compared to Humacyte's net margin of -4,556.29%. Edesa Biotech's return on equity of -560.22% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Humacyte	-4,556.29%	-983.32%	-88.84%

Edesa Biotech presently has a consensus target price of $5.00, suggesting a potential upside of 14.68%. Humacyte has a consensus target price of $6.54, suggesting a potential upside of 1,070.24%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Edesa Biotech has higher earnings, but lower revenue than Humacyte. Edesa Biotech is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Humacyte	$2.04M	76.12	-$40.83M	-$0.49	N/A

In the previous week, Humacyte had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.27 beat Humacyte's score of 0.92 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Humacyte beats Edesa Biotech on 10 of the 16 factors compared between the two stocks.

How does Edesa Biotech compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Edesa Biotech has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Edesa Biotech	N/A	-560.22%	-105.74%

Caribou Biosciences has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Edesa Biotech has lower revenue, but higher earnings than Caribou Biosciences. Edesa Biotech is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	12.34	-$148.12M	-$1.08	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

In the previous week, Edesa Biotech had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.89 beat Edesa Biotech's score of 1.27 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Caribou Biosciences	Very Positive
Edesa Biotech	Positive

Caribou Biosciences currently has a consensus price target of $7.75, indicating a potential upside of 503.11%. Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 14.68%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Caribou Biosciences beats Edesa Biotech on 11 of the 15 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EDSA vs. The Competition

Export

Metric	Edesa Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.03M	$3.87B	$7.20B	$12.67B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-2.58	15.12	275.02	25.43
Price / Sales	N/A	1,415.04	638.08	88.25
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	9.69	15.06	10.32	6.23
Net Income	-$7.19M	-$22.86M	$3.50B	$358.31M
7 Day Performance	-7.82%	-2.17%	-2.41%	-1.59%
1 Month Performance	-18.50%	1.84%	0.22%	-2.89%
1 Year Performance	78.03%	42.42%	24.17%	8.22%

Edesa Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EDSA Edesa Biotech	1.9748 of 5 stars	$4.36 +3.1%	$5.00 +14.7%	+72.7%	$42.03M	N/A	N/A	20	Positive News
MOLN Molecular Partners	2.6243 of 5 stars	$4.23 -6.0%	$8.38 +98.0%	+13.4%	$181.69M	$5.65M	N/A	180	Positive News Gap Down
NGEN NervGen Pharma	2.1219 of 5 stars	$2.32 +5.0%	$14.00 +503.4%	N/A	$178.19M	N/A	N/A	N/A
SPRB Spruce Biosciences	2.5451 of 5 stars	$55.60 -5.7%	$159.50 +186.9%	+333.1%	$169.48M	N/A	N/A	20
HUMA Humacyte	3.2017 of 5 stars	$0.57 -5.2%	$6.54 +1,046.9%	-61.4%	$167.07M	$2.04M	N/A	150	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EDSA) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edesa Biotech (EDSA) Competitors

EDSA vs. MOLN, NGEN, SPRB, HUMA, and CRBU

How does Edesa Biotech compare to Molecular Partners?

Summary

How does Edesa Biotech compare to NervGen Pharma?

Summary

How does Edesa Biotech compare to Spruce Biosciences?

Summary

How does Edesa Biotech compare to Humacyte?

Summary

How does Edesa Biotech compare to Caribou Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edesa Biotech (EDSA) Competitors

EDSA vs. MOLN, NGEN, SPRB, HUMA, and CRBU

How does Edesa Biotech compare to Molecular Partners?

Do analysts recommend EDSA or MOLN?

Which has stronger earnings & valuation, EDSA or MOLN?

Does the media refer more to EDSA or MOLN?

Do institutionals & insiders hold more shares of EDSA or MOLN?

Which has more volatility and risk, EDSA or MOLN?

Is EDSA or MOLN more profitable?

Summary

How does Edesa Biotech compare to NervGen Pharma?

Is EDSA or NGEN more profitable?

Do insiders and institutionals have more ownership in EDSA or NGEN?

Which has better valuation & earnings, EDSA or NGEN?

Does the media prefer EDSA or NGEN?

Do analysts prefer EDSA or NGEN?

Summary

How does Edesa Biotech compare to Spruce Biosciences?

Which has higher valuation & earnings, EDSA or SPRB?

Does the media favor EDSA or SPRB?

Is EDSA or SPRB more profitable?

Which has more risk & volatility, EDSA or SPRB?

Do analysts prefer EDSA or SPRB?

Do institutionals and insiders believe in EDSA or SPRB?

Summary

How does Edesa Biotech compare to Humacyte?

Is EDSA or HUMA more profitable?

Do analysts prefer EDSA or HUMA?

Which has preferable valuation & earnings, EDSA or HUMA?

Does the media prefer EDSA or HUMA?

Which has more risk & volatility, EDSA or HUMA?

Do institutionals and insiders have more ownership in EDSA or HUMA?

Summary

How does Edesa Biotech compare to Caribou Biosciences?

Is CRBU or EDSA more profitable?

Which has more risk & volatility, CRBU or EDSA?

Do insiders & institutionals believe in CRBU or EDSA?

Which has better valuation and earnings, CRBU or EDSA?

Does the media refer more to CRBU or EDSA?

Do analysts prefer CRBU or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDSA vs. The Competition

Edesa Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools